- Home
- EIC vs KROS Comparison
EIC vs KROS Comparison
Compare EIC & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EIC | KROS |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.8M | 222.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EIC | KROS |
|---|---|---|
| Price | $10.54 | $10.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $12.63 | ★ $21.86 |
| AVG Volume (30 Days) | 97.0K | ★ 299.5K |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 13.25% | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.17 | $9.79 |
| 52 Week High | $13.92 | $22.55 |
Technical Indicators
Market Signals| Indicator | EIC | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 51.73 | 39.31 |
| Support Level | $10.37 | $9.79 |
| Resistance Level | $11.34 | $12.43 |
| Average True Range (ATR) | 0.18 | 0.55 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 32.61 | 29.89 |
Price Performance
Historical ComparisonAbout EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.